We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement
News

Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement

Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement
News

Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Marina Biotech, Inc. has announced that it has entered into a licensing agreement with Novartis for Marina Biotech's Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutics.

Marina Biotech will receive $1 million in upfront fees for the non-exclusive license.

"We are pleased to enter into this agreement with Novartis, a global leader in the development of human therapeutics," stated J. Michael French, President and Chief Executive Officer of Marina Biotech.

French continued, "Marina's CRN is quite versatile and can be used to create stable, highly active oligonucleotide therapeutics and, in particular, both single- and double-stranded oligos. We view this license as yet another important validation of our nucleic acid-based drug discovery."

Advertisement